Becaplermin
- Generic Name
- Becaplermin
- Brand Names
- Regranex
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 165101-51-9
- Unique Ingredient Identifier
- 1B56C968OA
- Background
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
- Indication
For topical treatment of skin ulcers (from diabetes)
- Associated Conditions
- Skin Ulcer
- Associated Therapies
- -
Tendinopathy Treatment Market 2034: Clinical Trials, EMA
Tendinopathy market poised for growth due to increasing prevalence, awareness, and emerging treatments by companies like MiMedx, Novartis, Ipsen, and others. Key therapies include secukinumab, PRP, MSCs, corticosteroids, nitroglycerin patches, BPC-157, collagen hydrolysate, and hyaluronic acid. Market drivers include aging populations, sports participation, biologics advancements, and early diagnosis. Barriers include high therapy costs, limited awareness in developing countries, lack of standardized protocols, and competing therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath